Reverse T3: Drugs That Distort This Test

What Reverse T3 Actually Measures

Reverse T3 is the metabolically inactive mirror image of triiodothyronine (T3). The thyroid gland secretes thyroxine (T4), and peripheral tissues convert T4 into either active T3 via type 1 and type 2 5'-deiodinase enzymes, or into inactive rT3 via type 3 deiodinase 1. The ratio of these two pathways shifts based on illness, caloric intake, and medication exposure.

Roughly 60 to 80% of circulating rT3 originates from peripheral deiodination of T4 rather than direct thyroid secretion. Under normal conditions, rT3 is cleared rapidly by type 1 deiodinase, keeping serum levels between 9.2 and 24.1 ng/dL in most reference laboratories 2. Any drug that inhibits type 1 deiodinase or increases type 3 deiodinase activity will push rT3 upward. Any drug that accelerates type 1 activity or reduces T4 substrate will push rT3 downward.

The test itself uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) or immunoassay. LC-MS/MS avoids antibody cross-reactivity and is the more reliable platform when drug interference is suspected 3.

Amiodarone: The Most Potent rT3 Elevator

Amiodarone contains 37% iodine by weight and delivers roughly 7.5 mg of free iodine per 200 mg tablet daily. This iodine load inhibits type 1 and type 2 5'-deiodinase enzymes within days of initiation 4. The result is a predictable metabolic pattern: serum T4 and rT3 rise, free T3 falls, and TSH transiently increases during the first three months of therapy.

A 1990 study of 36 patients on chronic amiodarone therapy found that mean rT3 concentrations reached 45.2 ng/dL, approximately 2.5 times the upper reference limit, while free T3 dropped 20 to 30% below baseline 5. These changes persisted for the duration of amiodarone therapy and resolved slowly after discontinuation because of the drug's 40- to 55-day half-life.

The practical implication is straightforward. Any rT3 value drawn on a patient taking amiodarone is uninterpretable by standard reference ranges. Clinicians should rely on TSH and free T4 instead, as the American Thyroid Association (ATA) recommends for amiodarone-exposed patients 6.

Beta-Blockers: Propranolol vs. Cardioselective Agents

Not all beta-blockers affect rT3 equally. Propranolol inhibits type 1 5'-deiodinase at therapeutic doses (80 to 240 mg/day), reducing T4-to-T3 conversion and raising rT3 by 10 to 30% in published case series 7. This effect is dose-dependent and becomes clinically measurable at doses above 80 mg/day.

Cardioselective agents like metoprolol and atenolol do not share this property. A controlled study comparing propranolol 160 mg/day to atenolol 100 mg/day over four weeks showed significant rT3 elevation only in the propranolol group 8. The mechanism appears to be direct enzyme inhibition unrelated to beta-1 selectivity.

For patients on propranolol who need rT3 testing, a two-week washout is ideal but often impractical. Documenting propranolol use on the lab order allows the interpreting clinician to adjust expectations.

Corticosteroids: Acute vs. Chronic Effects

Glucocorticoids suppress T4-to-T3 conversion through multiple mechanisms. Dexamethasone at doses of 2 to 4 mg/day reduces type 1 deiodinase mRNA expression in the liver and increases rT3 by 15 to 40% within 48 hours of administration 9. Prednisone at doses above 20 mg/day produces a similar but less pronounced shift.

Chronic corticosteroid use adds a second variable: hypothalamic-pituitary suppression. Long-term glucocorticoid therapy can lower TSH independently, creating a thyroid panel that mimics both nonthyroidal illness syndrome and central hypothyroidism simultaneously 10. Distinguishing drug effect from true thyroid dysfunction requires knowing the exact corticosteroid dose and duration.

Dr. Elizabeth Pearce, professor of medicine at Boston University School of Medicine, has noted: "Glucocorticoids are one of the most common causes of altered thyroid function tests in hospitalized patients, and rT3 elevation is a predictable part of that pattern" 6.

Propylthiouracil and Methimazole

Propylthiouracil (PTU) has a dual mechanism: it blocks thyroid peroxidase inside the gland and inhibits peripheral type 1 deiodinase 11. This peripheral effect raises rT3 concentrations during the first weeks of treatment. Methimazole, by contrast, acts only within the thyroid gland and does not alter peripheral deiodination. A study in Graves' disease patients showed that PTU increased rT3 by approximately 25% compared to baseline, while methimazole-treated patients showed no significant rT3 change 12.

This distinction matters clinically. A patient switched from methimazole to PTU who then shows rising rT3 is likely experiencing a drug effect, not worsening thyroid disease or nonthyroidal illness.

Iodinated Contrast Media

Radiocontrast agents deliver a massive iodine bolus (typically 15,000 to 50,000 mg per CT scan). This acute iodine load inhibits deiodinase activity through substrate inhibition and the Wolff-Chaikoff effect 13. rT3 concentrations may rise within 24 to 48 hours of contrast administration and remain elevated for four to eight weeks depending on renal clearance.

A prospective study of 52 euthyroid patients undergoing contrast-enhanced CT showed mean rT3 increases of 35% at one week post-contrast, with normalization by week six in patients with normal renal function 14. Patients with chronic kidney disease showed prolonged elevation lasting up to 12 weeks.

The bottom line: defer rT3 testing for at least six weeks after any iodinated contrast exposure.

Anticonvulsants and Hepatic Enzyme Inducers

Phenytoin, carbamazepine, and phenobarbital induce hepatic cytochrome P450 enzymes and increase T4 clearance through glucuronidation 15. This accelerated T4 metabolism reduces the substrate available for rT3 production, potentially lowering rT3 into the low-normal range. The effect is counterintuitive: these drugs often lower both T4 and rT3 simultaneously while free T3 may remain normal.

Phenytoin also displaces T4 from thyroxine-binding globulin (TBG), which transiently increases free T4 availability to deiodinase enzymes. The net effect on rT3 depends on which mechanism dominates and may vary between patients. Serial measurements two to three months apart provide a more reliable picture than a single time point.

Lithium and Psychiatric Medications

Lithium inhibits thyroid hormone release from the gland, and roughly 20 to 30% of patients on long-term lithium develop subclinical or overt hypothyroidism 16. The compensatory TSH rise increases T4 production in the remaining functional tissue, which can either maintain or slightly raise rT3 depending on deiodinase activity.

Sertraline and other SSRIs have shown modest effects on thyroid hormone metabolism in some studies, though the clinical significance for rT3 specifically remains unclear. A 2012 review found no consistent SSRI effect on rT3 across controlled trials 17.

How to Interpret rT3 When Patients Are on These Drugs

The Endocrine Society and the ATA do not recommend rT3 as a routine thyroid screening test 6. The 2014 ATA hypothyroidism guidelines explicitly state that rT3 measurement should not guide levothyroxine dosing decisions 18. This caution exists precisely because so many variables, including medications, illness severity, caloric intake, and assay methodology, alter rT3 independently of thyroid function.

When rT3 is ordered despite these caveats, the interpreting clinician should document every medication the patient takes and compare against the known interference list. A practical approach:

1. Record the exact dose and duration of every drug on the interference list.
2. If the patient is on amiodarone or within 8 weeks of iodinated contrast, do not interpret rT3 at all.
3. For propranolol, PTU, or corticosteroids, expect rT3 to be 15 to 40% above true baseline.
4. For anticonvulsants, expect rT3 to be low-normal or below expected range.
5. Use TSH and free T4 as the primary diagnostic pair. Add free T3 if clinical suspicion for T3 thyrotoxicosis or nonthyroidal illness exists.

The American Association of Clinical Endocrinology (AACE) 2012 thyroid guidelines reinforce that TSH remains the single most reliable screening test for thyroid dysfunction, with rT3 reserved for specialized clinical scenarios such as differentiating euthyroid sick syndrome from central hypothyroidism 19.

Non-Drug Factors That Mimic Drug-Induced rT3 Shifts

Caloric restriction below 800 kcal/day reliably raises rT3 within 48 to 72 hours. A classic 1978 study showed that fasting for five days doubled rT3 concentrations in healthy volunteers 20. This "low T3 syndrome" or nonthyroidal illness syndrome (NTIS) is the body's energy-conservation response and is not a thyroid disease.

Critical illness produces the same pattern. ICU patients commonly show elevated rT3, low free T3, and low-normal TSH without having any primary thyroid pathology 21. Sepsis, major surgery, burns, and acute myocardial infarction all trigger this response. Interpreting rT3 in an ICU patient who is also receiving corticosteroids, propranolol for rate control, and recently had contrast imaging creates a layered interference problem that no single reference range can resolve.

Dr. Antonio Bianco, professor of medicine at the University of Chicago, has stated: "Reverse T3 is a metabolic thermostat, not a disease marker. It rises whenever the body needs to conserve energy, whether from illness, starvation, or pharmacologic interference with deiodinase enzymes" 1.

How to Lower Reverse T3

Lowering rT3 starts with identifying what raised it. If a medication is the cause, dose reduction or substitution (e.g., switching propranolol to metoprolol, or PTU to methimazole) is the most direct intervention 8. If caloric restriction or illness is the driver, restoring adequate nutrition and treating the underlying condition will normalize rT3 within days to weeks.

Selenium supplementation (200 mcg/day) has shown modest effects on deiodinase activity in selenium-deficient populations. A randomized trial in autoimmune thyroiditis patients found that selenium reduced rT3 by approximately 10% over six months, though the result was not statistically significant in selenium-replete individuals 22. Iron repletion in iron-deficient patients also supports normal deiodinase function.

There is no FDA-approved medication specifically indicated to lower rT3. Prescribing liothyronine (T3) to "overcome" elevated rT3 is not supported by any randomized controlled trial and carries the risk of iatrogenic thyrotoxicosis 18.